Nuvation Bio Inc.

Nuvation Bio Inc. (NYSE: NUVB) is a clinical-stage oncology company that entered the public markets in 2022 through a de-SPAC merger with Panacea Acquisition Corp. II, a blank-check vehicle that completed its IPO in 2021 under ticker PANA and was sponsored by Panacea Acquisition Holdings II LLC, an affiliate of biosciences-focused investment firm EcoR1 Capital. Nuvation Bio is focused on developing novel small-molecule therapies for cancer, with a pipeline targeting treatment-resistance mechanisms across multiple oncology indications. The company filed an 8-K with the SEC on March 25, 2024, continuing its post-merger reporting obligations as a listed healthcare issuer. For complete deal history, pipeline data, and SPAC market analytics on Nuvation Bio and thousands of other transactions, sign up for full access at SpacDesk.